This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Mark Schlegel, PhD
Principal Scientist, RNAi Discovery at Alnylam Pharmaceuticals


Mark joined Alnylam Pharmaceuticals in 2014 where he is currently a Principal Scientist in the RNAi Discovery group.  At Alnylam, Mark leads the high throughput RNA synthesis team, the siRNA lead discovery team, and several platform development efforts.  Prior to joining Alnylam, Mark held the position of Head of Automation at GlycoUniverse GmbH & CO KGaA.  Mark received his undergraduate degree in chemistry from Moravian College, a PhD in Chemical Biology from the University of Pennsylvania, and was a postdoctoral fellow at the Max Planck Institute of Colloids and Interfaces.

Agenda Sessions

  • Improved Specificity of Conjugate siRNAs Through Chemical Modification

    On Demand
  • Medicinal Chemistry of RNA Therapeutics


Speakers at this event